CURRICULUM VITAE

Prof. Dr. NECDET ÜSKENT, MD

I. PRESENT ACADEMIC RANK AND POSITION

2006-Present Professor of Internal Medicine

Proffessor of Medical Oncology
Professor of Hematology

Anadolu Medical Center ( affiliated with John's Hopkins University)

Institute of Oncology

II. EDUCATION

University : University of Ankara School of Medicine, 1971

Residency : GATA, Internal Medicine, 1975-1979

Fellowship : University of Texas, Hematology & Oncology, 1979-1982

Other : University of London Charing Cross Hospital-UK,

Bone Marrow Transplantation, 1986 April-October (6 months)

University of Basel, Kantonsspital Basel-Switzerland

Loco-regional Chemotherapy, 1989 September-January (3 months)

University of London, Royal Free Hospital

Stem Cell Transplantation, 1998

III. BOARD CERTIFICATION

Internal Medicine, 1979

Medical Oncology, 1983
Hematology, 1983

IV. MEDICAL LICENSURE

Texas license - licence number: G 1791

Georgia licence – licence number: 22971
ESMO Medical oncology certificate – certificate number: 258-495-1

V. PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS

1982-1984 Assistant Proffessor of Internal Medicine, GATA Department of Internal Medicine

1984-1989 Associate Proffessor of Internal Medicine, GATA Department of Internal Medicine,
Division of Medical Oncology
1989-2001 Proffessor of Internal Medicine, GATA Department of Internal Medicine ( Director )
Chief of Hematology &Oncology Department
2001-2006 Proffessor of Internal Medicine, Kadir Has Univeersity School of Medicine
Chief of Internal Medicine Department

VI. EDUCATION—TEACHING

Medical School : GATA School of Medicine: Classes 3 , 4 and 6, 1984-2001

University of Marmara School of Medicine: Classes 3 and 4, 1987-1990
Kadir Has University, School of Medicine: Classes 3 and 4, 2001-2006
Graduate School : İstanbul University Çapa Institute of Oncology
Courses for Doctorate Students, 1990-1992
Continuing Education : ESMO Courses in Antalya, İstanbul, and Ankara
Medical Oncology Courses in National Cancer Congresses
New Trends in Oncology-İstanbul, 2008 and 2009

Prof.Dr.Necdet Üskent-CV 1
 VII. EDUCATION—JOURNALS

Member of Editorial Board and Reviewer of

• Journal of Hematology and Oncology (Turkey),
• Cancer (Turkey),
• Journal of Oncology (Turkey),
• New Drugs (International)

VIII. PROFESSIONAL AND SOCIETY MEMBERSHIPS

ASCO (American Society of Clinical Oncology)

ESMO (European Society of Medical Oncology)
National Society of Medical Oncology
Turkish Associaton of Hematology

IX. INVITED VISITING PROFESSORSHIPS

University of London, Charing Cross and Westminster Medical School,1986

University of London Royal Free Hospital, 1998

X. PRESENTATIONS AT NATIONAL MEETINGS

More than 200 Oral Presentations in National Meetings*

XI. PRESENTATIONS AT INTERNATIONAL MEETINGS

More than 100 abstracts and oral presentations in International Cogresses *

XII. INTRAMURAL PRESENTATIONS

Oncology Board, Grand Rounds and Journal Clubs weekly

XIII. CLINICAL PRACTICE, INTERESTS, AND ACCOMPLISHMENTS

Breast cancer, Lung cancer, Gastrointestinal Cancers,Lymphoma, Melanoma,Myeloma,Cancer

Vaccines and Targeted therapies

XIV. RESEARCH INTERESTS

Cancer Vaccines and Gene Therapies

International Multi-National Multicentric and National Multicentric Phase 3 Studies:
1. ISEL Study: Gefitinib in Placebo randomised double blind phase III study in Previously Treated Resistent or Progressive
Non-Small Cell Lung Cancer, 2004
2. Efficacy of Docataxel as a First Line Single Agent Compare to Docataxel+ Cisplatin in Stage III/IV Non-Small Cell Lung
Cancer, Phase III, Randomised Study, 2000
3. Florourasil+ Leucovorine vs Florourasil+ alpha Inteferon in metastatic Colorectal cancer, Phase III, Randomised Study, 1999
4. Neoadjuvant FOLFİRİ vs FOLFOX in the resectability of liver metastases in colo-rectal cancer,Randomized National
Multicentric Study
5. Anastrozol Farmacovijilans Study in Early Postmenapausal Breast Cancer Patients,in Turkey. Multicentric National Study
(Coordinator), 2008
6. Interferon Maintenance in Multiple Myeloma patients in plato phase, multinational, multicentric study, 1997
7. A Phase III Clinical Trial to Evaluate the safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7. Compared to
Dacarbazine(DTIC) or Temozolamide (TMZ) in Subjects with Recurren Metastatic Melanoma Randomized 2010

XV. BIBLIOGRAPHY
More than 200 published articles in National and Internatinal Journals*
* List of details can be shared upon the request.

Prof.Dr.Necdet Üskent-CV 2